Lyell Immunopharma (LYEL) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Lyell Immunopharma (LYEL) overview

Lyell Immunopharma (LYEL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.0m and operating profit of USD -269m; the year-end share price was 30.78 USD and market capitalisation was USD 654m. Lyell Immunopharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Lyell Immunopharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 248mFY 2025
Share price30.78 USDFY 2025 year end
RevenueUSD 0.0mFY 2025
Operating profitUSD -269mFY 2025
Net earningsUSD -274mFY 2025
Market capitalisationUSD 654mFY 2025 year end

About Lyell Immunopharma

Lyell is a clinical-stage cell therapy company developing autologous CAR T-cell product candidates for cancer. Its therapies use patients’ own immune cells, engineered with CAR constructs and other enhancements intended to support cancer cell killing. The company’s clinical programs address hematologic malignancies, including large B-cell lymphoma, and solid tumors, including metastatic colorectal cancer.

Generate the Lyell Immunopharma report

Lyell Immunopharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Lyell Immunopharma and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Lyell Immunopharma

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.